fbpx

Aerie Pharmaceuticals Announces Appointment of William Coppola as Intellectual Property Counsel

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical
company focused on the discovery, development and commercialization of
first-in-class therapies for the treatment of patients with open-angle
glaucoma and other diseases of the eye, today announced the appointment
of William Coppola as Intellectual Property Counsel, reporting to John
LaRocca, Aerie’s General Counsel. Mr. Coppola will oversee intellectual
property matters both domestically and internationally on behalf of the
Company. Mr. Coppola previously held related positions at Sanofi.

In connection with his acceptance of the position as Intellectual
Property Counsel, Mr. Coppola will receive awards totaling 14,400 stock
options that will vest over 4 years, with 25% vesting on the first
anniversary of the hire date and the remainder vesting ratably on each
of the subsequent 36 monthly anniversaries of the hire date. This award
was made outside of Aerie’s stockholder-approved equity incentive plan
and was approved by the Company’s independent directors as an inducement
material to Mr. Coppola entering into employment with the Company in
reliance on NASDAQ Listing Rule 5635(c)(4), which requires this public
announcement.

About Aerie Pharmaceuticals, Inc.

Aerie is an ophthalmic pharmaceutical company focused on the discovery,
development and commercialization of first-in-class therapies for the
treatment of patients with open-angle glaucoma and other diseases of the
eye. Aerie’s first product, Rhopressa® (netarsudil ophthalmic
solution) 0.02%, for the reduction of elevated intraocular pressure
(IOP) in patients with open-angle glaucoma or ocular hypertension, was
approved by the U.S. Food and Drug Administration (FDA) in December 2017
and was launched in the U.S. market in April 2018. A link to the full
product label is available on the Aerie website at http://investors.aeriepharma.com.
Aerie’s advanced-stage product candidate, Roclatan™
(netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%, which is a
fixed dose combination of Rhopressa® and widely-prescribed
PGA (prostaglandin analog) latanoprost, achieved its primary efficacy
endpoint in two Phase 3 registration trials, named Mercury 1 and Mercury
2, and also achieved successful 12-month safety and efficacy results in
Mercury 1. The Roclatan™ NDA submission took place in May 2018. Aerie is
also focused on global expansion and the development of additional
product candidates and technologies in ophthalmology.

Forward-Looking Statements

This press release contains forward-looking statements for purposes of
the safe harbor provisions of the Private Securities Litigation Reform
Act of 1995. We may, in some cases, use terms such as “predicts,”
“believes,” “potential,” “proposed,” “continue,” “estimates,”
“anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,”
“will,” “should,” “exploring,” “pursuing” or other words that convey
uncertainty of future events or outcomes to identify these
forward-looking statements. Forward-looking statements include
statements regarding our intentions, beliefs, projections, outlook,
analyses or current expectations concerning, among other things: our
expectations regarding the commercial launch and sales of Rhopressa®
and Roclatan™ and any future product candidates, if approved; our
commercialization, marketing, manufacturing and supply management
capabilities and strategies; third-party payer coverage and
reimbursement of Rhopressa® and Roclatan™ and any future
product candidates, if approved; the glaucoma patient market size and
the rate and degree of market adoption of Rhopressa® and
Roclatan™ and any future product candidates, if approved, by eye-care
professionals and patients; the timing cost or other aspects of the
commercial launch of Rhopressa® and Roclatan™ and any future
product candidates, if approved; the success, timing and cost of our
ongoing and anticipated preclinical studies and clinical trials for
Rhopressa®, with respect to regulatory approval outside the
United States, and Roclatan™ and any future product candidates,
including statements regarding the timing of initiation and completion
of the studies and trials; our expectations regarding the effectiveness
of Rhopressa®, Roclatan™ and any future product candidates
and results of our clinical trials and any potential preclinical
studies; the timing of and our ability to request, obtain and maintain
FDA or other regulatory authority approval of, or other action with
respect to, as applicable, Rhopressa®, Roclatan™
and any future product candidates in the United States, Canada, Europe,
Japan and elsewhere, including the expected timing of, and regulatory
and/or other review of, filings for, as applicable, Rhopressa®,
Roclatan™ and any future product candidates; the potential advantages of
Rhopressa®, Roclatan™ and any future product
candidates; our plans to pursue development of additional product
candidates and technologies in ophthalmology, including development of
Rhopressa® and Roclatan™ for additional indications, our
preclinical retina programs and other therapeutic opportunities; our
plans to explore possible uses of our existing proprietary compounds
beyond glaucoma and ophthalmology; our ability to protect our
proprietary technology and enforce our intellectual property rights; and
our expectations regarding collaborations, licensing, acquisitions and
strategic operations, including our ability to in-license or acquire
additional ophthalmic products, product candidates or technologies. By
their nature, forward-looking statements involve risks and uncertainties
because they relate to events, competitive dynamics, industry change and
other factors beyond our control, and depend on regulatory approvals and
economic and other environmental circumstances that may or may not occur
in the future or may occur on longer or shorter timelines than
anticipated. We discuss many of these risks in greater detail under the
heading “Risk Factors” in the quarterly and annual reports that we file
with the Securities and Exchange Commission (SEC). In particular, FDA
approval of Rhopressa® does not constitute FDA approval of
Roclatan™, and there can be no assurance that we will receive FDA
approval for Roclatan™ or any future product candidates. FDA approval of
Rhopressa® also does not constitute regulatory approval of
Rhopressa® in jurisdictions outside the United States, and
there can be no assurance that Rhopressa® will obtain
regulatory approval in other jurisdictions. Forward-looking statements
are not guarantees of future performance and our actual results of
operations, financial condition and liquidity, and the development of
the industry in which we operate may differ materially from the
forward-looking statements contained in this press release. Any
forward-looking statements that we make in this press release speak only
as of the date of this press release. We assume no obligation to update
our forward-looking statements whether as a result of new information,
future events or otherwise, after the date of this press release.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180618005007/en/